Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada
about
Prescription Patterns of Medications for Alzheimer's Disease in Japan from 2010 to 2015: A Descriptive Pharmacy Claims Database StudyAcquired Localized Hypertrichosis Induced by Rivastigmine.Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching.Complementary medicine for treatment of agitation and delirium in older persons: a systematic review and narrative synthesis.Therapeutic Potentials of Microalgae in the Treatment of Alzheimer's Disease.Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation.A Systematic Review of Practice Guidelines and Recommendations for Discontinuation of Cholinesterase Inhibitors in Dementia.Cholinesterase Inhibitory Activities of Adamantyl-Based Derivatives and Their Molecular Docking Studies.Cholinesterases and the fine line between poison and remedy.An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine.Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer's disease.A simple method for exploring adverse drug events in patients with different primary diseases using spontaneous reporting system.A New Search Method Using Association Rule Mining for Drug-Drug Interaction Based on Spontaneous Report System.Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System.Efficacy and Safety of MLC601 in Patients with Mild to Moderate Alzheimer Disease: An Extension 4-Year Follow-Up Study.
P2860
Q33736188-6E92D327-2137-4545-BFDB-F2AC9CB03A67Q36747587-E5AE4DAD-E40F-4D69-96AF-AE7616FC95EEQ38990600-554A7FFE-3526-46E3-9388-D266B87A12A4Q39152167-7DE65A53-C390-4EDE-912D-F88891CD879FQ39196662-3DB05172-3233-43EF-98E6-60282F98183AQ39415447-9664A8CB-AB2D-4DC5-8BA2-EA12763C9B94Q47571627-DD317FA8-D472-4216-8404-C44FA13CD191Q48005010-AF2959AA-65A1-471D-9196-CC70293ED83BQ50152965-357D7823-FE1C-4669-9823-573AF2B66031Q50328399-B03D5F20-ED90-4C90-AD83-5629CBC3083BQ51491144-176F428F-D655-42ED-A08A-9349209FAD0BQ52604170-E02338FE-BA57-4D74-9859-76F339E20114Q52624670-9CEDCA9D-47E3-49B3-A111-2D88C35F2804Q54234367-A044DA81-C9B9-4ED3-86DA-87264B4DA0B2Q55093805-39C8E109-F0D1-4CBC-AE50-D9CCF3947B83
P2860
Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Adverse Effects of Cholinester ...... f the United-States and Canada
@ast
Adverse Effects of Cholinester ...... f the United-States and Canada
@en
Adverse Effects of Cholinester ...... f the United-States and Canada
@nl
type
label
Adverse Effects of Cholinester ...... f the United-States and Canada
@ast
Adverse Effects of Cholinester ...... f the United-States and Canada
@en
Adverse Effects of Cholinester ...... f the United-States and Canada
@nl
prefLabel
Adverse Effects of Cholinester ...... f the United-States and Canada
@ast
Adverse Effects of Cholinester ...... f the United-States and Canada
@en
Adverse Effects of Cholinester ...... f the United-States and Canada
@nl
P2093
P2860
P1433
P1476
Adverse Effects of Cholinester ...... f the United-States and Canada
@en
P2093
Thibault B Ali
Thomas R Schleret
Winston Yuchen Chen
P2860
P304
P356
10.1371/JOURNAL.PONE.0144337
P407
P577
2015-01-01T00:00:00Z